Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149349 | 0.89 | MGLL (0.59) | MGLLMEN1KMT2ASLC6A7TNKS | |
| SCHEMBL144730 | 0.89 | MGLL (0.59) | MGLLMEN1KMT2ASLC6A7TNKS | |
| SCHEMBL145187 | 0.86 | MGLL (0.56) | MGLLSLC6A7TNKSFAAH | |
| SCHEMBL145770 | 0.85 | MGLL (0.60) | MGLLMEN1KMT2ATNKSFAAH | |
| SCHEMBL16564154 | 0.83 | MEN1 (0.54) | MGLLMEN1KMT2ACHRNB2CHRNB4 | |
| SCHEMBL148823 | 0.83 | MGLL (0.62) | MGLLMEN1KMT2ASLC6A7TNKS | |
| SCHEMBL145555 | 0.80 | MGLL (0.64) | MGLLMEN1KMT2ATNKSFAAH | |
| SCHEMBL145402 | 0.80 | MGLL (0.60) | MGLLSLC6A7FAAH | |
| SCHEMBL148745 | 0.79 | MGLL (0.74) | MGLLTNKSFAAH | |
| SCHEMBL145592 | 0.79 | MGLL (0.58) | MGLLSLC6A7TNKSFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | disclosed |
| US-8759533-B2 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759333-B2 | Di-azetidinyl diamide as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196969-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885MEN1 2640/4885KMT2A 2355/4885 |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885MEN1 2640/4885KMT2A 2355/4885 |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MGLL 4/4885MEN1 3178/4885KMT2A 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.